ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 141 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2021. The put-call ratio across all filers is 1.72 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $224,135 | +0.0% | 228,710 | +41.9% | 0.00% | – |
| Q2 2023 | $224,109 | -79.2% | 161,230 | -76.2% | 0.00% | – |
| Q1 2023 | $1,075,352 | -74.0% | 676,322 | +1.7% | 0.00% | -100.0% |
| Q4 2022 | $4,143,467 | +6.2% | 665,083 | +14.3% | 0.00% | 0.0% |
| Q3 2022 | $3,900,000 | +8.0% | 582,008 | +2.5% | 0.00% | 0.0% |
| Q2 2022 | $3,611,000 | +48.0% | 567,696 | +8.0% | 0.00% | – |
| Q1 2022 | $2,440,000 | +44.7% | 525,840 | +56.0% | 0.00% | – |
| Q4 2021 | $1,686,000 | -52.5% | 337,157 | +14.4% | 0.00% | -100.0% |
| Q3 2021 | $3,553,000 | -46.3% | 294,842 | -5.8% | 0.00% | 0.0% |
| Q2 2021 | $6,617,000 | -22.6% | 312,888 | +2.6% | 0.00% | -50.0% |
| Q1 2021 | $8,554,000 | +1.1% | 304,925 | -6.2% | 0.00% | 0.0% |
| Q4 2020 | $8,457,000 | -32.7% | 325,244 | -3.8% | 0.00% | -33.3% |
| Q3 2020 | $12,565,000 | -30.6% | 338,067 | -4.2% | 0.00% | -25.0% |
| Q2 2020 | $18,098,000 | +82.8% | 352,722 | +12.4% | 0.00% | +33.3% |
| Q1 2020 | $9,898,000 | -46.5% | 313,933 | +1.2% | 0.00% | -25.0% |
| Q4 2019 | $18,506,000 | +58.7% | 310,362 | -2.4% | 0.00% | +33.3% |
| Q3 2019 | $11,659,000 | -14.4% | 318,042 | +8.6% | 0.00% | 0.0% |
| Q2 2019 | $13,617,000 | +16.9% | 292,722 | +0.9% | 0.00% | 0.0% |
| Q1 2019 | $11,644,000 | -12.1% | 290,033 | +0.8% | 0.00% | -25.0% |
| Q4 2018 | $13,240,000 | -52.4% | 287,827 | -54.1% | 0.00% | -42.9% |
| Q3 2018 | $27,804,000 | +20.2% | 626,639 | +6.2% | 0.01% | +16.7% |
| Q2 2018 | $23,126,000 | -44.8% | 590,104 | +1.8% | 0.01% | -45.5% |
| Q1 2018 | $41,909,000 | +10.8% | 579,402 | +0.9% | 0.01% | +10.0% |
| Q4 2017 | $37,817,000 | +30.6% | 574,377 | -0.6% | 0.01% | +25.0% |
| Q3 2017 | $28,965,000 | +43.9% | 577,917 | +32.9% | 0.01% | +33.3% |
| Q2 2017 | $20,128,000 | +8.9% | 434,913 | -16.9% | 0.01% | +20.0% |
| Q1 2017 | $18,489,000 | +191.6% | 523,610 | +3.4% | 0.01% | +150.0% |
| Q4 2016 | $6,341,000 | -9.2% | 506,512 | +0.4% | 0.00% | 0.0% |
| Q3 2016 | $6,985,000 | +110.5% | 504,375 | +50.2% | 0.00% | +100.0% |
| Q2 2016 | $3,319,000 | -3.7% | 335,886 | +75.4% | 0.00% | 0.0% |
| Q1 2016 | $3,448,000 | -16.4% | 191,513 | +3.4% | 0.00% | 0.0% |
| Q4 2015 | $4,122,000 | -3.2% | 185,152 | +2.6% | 0.00% | 0.0% |
| Q3 2015 | $4,257,000 | -42.7% | 180,424 | +98.7% | 0.00% | -50.0% |
| Q2 2015 | $7,423,000 | +12.5% | 90,793 | +27.5% | 0.00% | 0.0% |
| Q1 2015 | $6,596,000 | +142.7% | 71,234 | +6.0% | 0.00% | +100.0% |
| Q4 2014 | $2,718,000 | +118.5% | 67,214 | +32.2% | 0.00% | – |
| Q3 2014 | $1,244,000 | +49.3% | 50,842 | -3.2% | 0.00% | – |
| Q2 2014 | $833,000 | -6.5% | 52,534 | -10.9% | 0.00% | – |
| Q1 2014 | $891,000 | +1.4% | 58,978 | -7.8% | 0.00% | – |
| Q4 2013 | $879,000 | +127.1% | 63,998 | +212.0% | 0.00% | – |
| Q3 2013 | $387,000 | – | 20,515 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
| Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
| Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
| Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
| Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
| Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
| Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
| WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
| Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |